Photo credit: Jean-Marie Heidinger/Inserm
Row 1, left to right: Dominique Donnet-Kamel, Suzy Mouchet, Martine Bungener, Muriel Le Roux, Hélène Chambefort, Florence Hachez-Leroy
Row 2, left to right: Arnaud Benedetti, Pascal Griset, Yves Levy, André Syrota, Yves Agid, Pierre Corvol
Inserm announces the creation of its History Committee, reporting directly to its Chairman and Chief Executive Officer, Professor Yves Lévy. This Committee will be chaired by Professor Pascal Griset (Director of the Institute for Communication Sciences [ISCC], Paris-Sorbonne). This Committee is one of the actions conducted by the Institute in recent decades to reconstitute, preserve and promote its heritage, and as a continuation of the events that marked the 50th anniversary of the Institute in 2014.
A primary objective of the Committee will be to encourage and conduct work on the history of Inserm and of France’s biological, medical and health research in its national and international context, in order to raise the profile of Inserm’s activity within the French research system. The Committee will also be involved in enriching the Histoire de l’Inserm website (histoire.inserm.fr), and, in conjunction with university, scientific, cultural and socioeconomic circles, will promote or organise seminars, symposia, round-tables and any other events associated with Inserm’s history, and, more broadly, the history of medical and health research. Finally, this committee intends to provide a link with institutions working in these similar and/or complementary fields, and to design projects in partnership with them.
The Committee members
Nine members appointed by the Chairman and Chief Executive Officer of Inserm for a renewable period of 4 years
To find out more
The French Plan for Genomic Medicine 2025 was presented to Prime Minister Manuel Valls by Yves Lévy, President of the National Alliance for Life Sciences and Health (Aviesan) and CEO of Inserm, on 22 June 2016. ...
Des scientifiques provenant de 6 pays, réunis au sein du projet ENS@T-HT mettent en commun leur expertise afin d’améliorer le diagnostic et la prise en charge thérapeutique de l’hypertension artérielle primaire et secondaire par une approche axée sur les « omiques ». ...